What is BIAF's earnings growth forecast for 2026-2026?
(NASDAQ: BIAF) Bioaffinity Technologies's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Bioaffinity Technologies's earnings in 2026 is -$15,185,242.
In 2026, BIAF is forecast to generate -$4,462,430 in earnings, with the lowest earnings forecast at -$4,287,433 and the highest earnings forecast at -$4,593,678.
What is BIAF's revenue growth forecast for 2026-2026?
(NASDAQ: BIAF) Bioaffinity Technologies's forecast annual revenue growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Bioaffinity Technologies's revenue in 2026 is $5,900,985.
In 2026, BIAF is forecast to generate $4,025,477 in revenue, with the lowest revenue forecast at $3,867,764 and the highest revenue forecast at $4,143,762.
What is BIAF's forecast return on assets (ROA) for 2026-2026?
(NASDAQ: BIAF) forecast ROA is -58.57%, which is lower than the forecast US Diagnostics & Research industry average of 8.11%.
What is BIAF's Earnings Per Share (EPS) forecast for 2026-2026?
(NASDAQ: BIAF) Bioaffinity Technologies's current Earnings Per Share (EPS) is -$109.70. In 2026, BIAF's EPS is forecast to hit -$8.26 (min: -$7.94, max: -$8.51).
What is BIAF's forecast return on equity (ROE) for 2026-2026?
(NASDAQ: BIAF) forecast ROE is -118.4%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.